Kisspeptin: new biomarker of pregnancy

Priyanka Meena¹, Rati Mathur¹, Mohan L. Meena²*

¹Department of Biochemistry, SMS Medical College and Attached Hospital, Jaipur, Rajasthan, India
²Department of Obstetrics and Gynecology, SMS Medical College and Attached Hospital, Jaipur, Rajasthan, India

Received: 30 May 2019
Accepted: 26 June 2019

*Correspondence:
Dr. Mohan L. Meena,
E-mail: drmohanmeena@gmail.com

Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

ABSTRACT

Background: The recently identified hormone kisspeptin has been suggested to play an important regulatory role in placentation. The aim and objective of the study is the measurement of serum kisspeptin level in asymptomatic pregnant women and to find out the association of serum kisspeptin with gestational age in women with early pregnancy.

Methods: This was a longitudinal study to the evaluation of 178 asymptomatic pregnant women with a gestation of 6 to 16 weeks attending routine antenatal booking visit recruited as study participants from the Antenatal Clinical of Obstetrics and Gynaecology Department, S.M.S. Medical College and Attached Hospitals, Jaipur, Rajasthan, India.

Results: After initial clinical examination of every participant, a single blood sample was taken for the measurement of serum kisspeptin. Serum kisspeptin measurement test was performed by ELISA method and results were expressed as ng/ml. Pregnancy outcome was recorded prospectively. Mean serum kisspeptin level of study participants was 2.80±1.87ng/ml and median were 2.41 (Range 0.244-14.06ng/ml). Our result showed the relationship of serum kisspeptin with gestational age (GA) (p<0.000).

Conclusions: serum kisspeptin level increases in pregnancy and showed positive relationship with gestational age significantly (p<0.000).

Keywords: Asymptomatic pregnant, Early pregnancy, Gestational age, Hormone, Kisspeptin

INTRODUCTION

Kisspeptin consists of a group of arginine-phenylalanine (RF) amide peptides encoded by the KISS1 gene, which binds to the kisspeptin receptor.¹,² Kisspeptin was first discovered in 1996 as a metastasis inhibitor in melanoma cell lines.³ In humans, the KISS1 gene that encodes kisspeptin is located on the long (q) arm of chromosome 1 at q32.³ Initially, this gene encodes an intermediate 145-amino-acid prepropeptide, which is unstable and biologically inactive. The prepropeptide is then cleaved into four biologically active peptides distinguished by their number of amino acids: kisspeptin-10, 13, 14 and 54 (52 in rodent animals). All kisspeptins contain the RF-amide motif that can bind and activate KISS1R.⁴,⁵ The most abundant kisspeptin in the human circulation is kisspeptin-54.⁶ KISS1R belongs to the G-protein-coupled receptor family that was first identified as an orphan receptor in the rat brain.⁷ Kisspeptin is expressed most abundantly in the syncytiotrophoblast cells of the placenta, in which it may regulate invasion into the maternal uterine wall.⁸,⁹ Kisspeptin is also expressed in certain areas of the brain such as hypothalamus, amygdala, and caudate nucleus in addition to the pituitary, pancreas, adipose, testis, lymphocytes, and spleen.¹⁰ Because kisspeptin is produced by trophoblasts
and trophoblast invasion is underway 5 days after blastocyst transplantation, plasma kisspeptin concentrations during the implantation period may reflect early developmental events associated with pregnancy outcome.\textsuperscript{11} It should be noted that the expression of KISS1 in the placenta or plasma kisspeptin levels may be affected by the adverse uterine environment.\textsuperscript{12,13} Plasma or serum kisspeptin levels are significantly increased in early pregnancy compared to non-pregnant controls.\textsuperscript{13-15}

**METHODS**

The present study was conducted in the Department of Biochemistry, in association with the Department of Obstetrics and Gynaecology, S.M.S. Medical College and Hospital, Jaipur, Rajasthan, India. A total of 178 asymptomatic pregnant women with a gestation age of 6 to 16 weeks attending routine antenatal booking visit, between June 2017 to November 2018, recruited as study participants. After taking written informed consent, a single blood sample was taken for the measurement of serum kisspeptin. Blood sample was collected in plane Vial .The serum was separated from the clotted specimen by centrifugation at 1300-1800 rpm for 10 minutes within 2 hours. Serum was stored at -20°C in aliquots for analysis and Kisspeptin was measured by ELISA method using the following kit used as per manufacturers’ instructions KISS1 (Fine Test, Wuhan Fine Biological Technology Co., Ltd.). Emergency admissions, cases of suspected miscarriage and women with renal failure were excluded. The protocol was approved by the institutional Ethics Committee. All pregnancies were dated according to an ultrasound scan performed in the antenatal clinic. Measurement of serum kisspeptin was performed using the Mindray MR-96 ELISA microplate reader and result were expressed as ng/ml; Range: 0.156-10 ng/ml; Sensitivity: <0.094 ng/ml.

**Statistical analysis**

Data were analyzed with the SPSS software version 23 .0 trial version for Windows (SPSS Inc., Chicago, IL, USA). Data are presented as Mean±SD. The difference in would be analyzed using ANOVA test.

**RESULTS**

The study comprised a total of 178 asymptomatic pregnant women as study participants.

<table>
<thead>
<tr>
<th>Variables</th>
<th>Mean±SD</th>
<th>Median</th>
<th>Range</th>
<th>Percentiles</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>25</td>
</tr>
<tr>
<td>Age (years.)</td>
<td>24.90±3.70</td>
<td>25.00</td>
<td>19-40</td>
<td>22.00</td>
</tr>
<tr>
<td>GA (days)</td>
<td>71.72±18.92</td>
<td>70.00</td>
<td>41-110</td>
<td>56.50</td>
</tr>
<tr>
<td>GA (weeks)</td>
<td>10.23±2.70</td>
<td>10.07</td>
<td>6-16</td>
<td>8.11</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>56.24±7.92</td>
<td>56.00</td>
<td>40-78</td>
<td>50.00</td>
</tr>
<tr>
<td>Height (cm)</td>
<td>156.12±4.90</td>
<td>156.00</td>
<td>146-170</td>
<td>152.00</td>
</tr>
<tr>
<td>BMI</td>
<td>23.71±3.34</td>
<td>23.61</td>
<td>16.87-32.89</td>
<td>21.08</td>
</tr>
<tr>
<td>SBP (mmHg)</td>
<td>114.85±5.96</td>
<td>110.00</td>
<td>90-130</td>
<td>110.00</td>
</tr>
<tr>
<td>DBP (mmHg)</td>
<td>74.10±5.43</td>
<td>70.00</td>
<td>60-80</td>
<td>70.00</td>
</tr>
</tbody>
</table>

**Table 2: Serum Kisspeptin level with gestational age in participants.**

<table>
<thead>
<tr>
<th>GA</th>
<th>N</th>
<th>Kisspeptin</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Mean</td>
</tr>
<tr>
<td>&lt;8</td>
<td>43</td>
<td>1.88</td>
</tr>
<tr>
<td>8 to 8.99</td>
<td>29</td>
<td>2.39</td>
</tr>
<tr>
<td>9 to 9.99</td>
<td>15</td>
<td>2.69</td>
</tr>
<tr>
<td>10 to 10.99</td>
<td>15</td>
<td>2.76</td>
</tr>
<tr>
<td>11 to 11.99</td>
<td>17</td>
<td>2.97</td>
</tr>
<tr>
<td>12 to 12.99</td>
<td>18</td>
<td>3.07</td>
</tr>
<tr>
<td>13 to 13.99</td>
<td>26</td>
<td>3.68</td>
</tr>
<tr>
<td>14 to 14.99</td>
<td>10</td>
<td>4.05</td>
</tr>
<tr>
<td>≥15</td>
<td>5</td>
<td>4.79</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>178</td>
<td>2.80</td>
</tr>
</tbody>
</table>

In Table 1 the mean maternal age, gestational age (GA) in days, GA in weeks, weight, height, body mass index (BMI), systolic blood pressure (SBP) and diastolic blood pressure (DBP) of study participants 24.90±3.70,
DISCUSSION

The present study was undertaken to measurement of kisspeptin in pregnant women and to find out the correlation between serum kisspeptin level and gestational age in pregnant women. Horikoshi et al, studied that the circulating kisspeptin levels were low in males and non-pregnant females (<2 pmol/l) but increase in pregnancy.\(^\text{14}\) In humans, the plasma concentration of kisspeptin increases dramatically in the pregnancy, with a 900-fold increase in the first trimester and further increases to over 7000-fold in the third trimester compared to the non-pregnant women.\(^\text{15}\) It is most likely that the increase in the total number of trophoblast cells throughout the course of gestation is responsible for the dramatic increase in serum kisspeptin levels.\(^\text{16}\) Kisspeptin are mainly derived from placenta, the levels of plasma or serum kisspeptin can probably act as a biomarker for the function of the placenta and therefore viability of pregnancy.\(^\text{17}\)\(^\text{19}\) Dhillon et al, showed that circulating kisspeptin levels fell again 5 days post-delivery to comparable concentrations prior to pregnancy, implicating a placental source.\(^\text{20}\) In support of a placental origin, plasma kisspeptin levels are increased in patients with gestational trophoblastic neoplasia and fall during and after treatment with chemotherapy. C. N. Jayasena, et al, revealed that the slope coefficient for correlation of kisspeptin levels with the time of gestation across the cohort of women who experienced miscarriage was significantly lower than for those who had an unaffected pregnancy suggests that a higher rate of increase in circulating plasma kisspeptin would be expected in a viable as compared with a failing pregnancy.\(^\text{15}\) Plasma kisspeptin significantly correlated with gestation (p value <0.0001).

Together, these results suggest that kisspeptin may be marker of the establishment of early pregnancy. Our study evaluated the serum kisspeptin in 178 asymptomatic pregnant women. We showed that kisspeptin level associated with gestational age significantly (p value <0.000) serum kisspeptin level would continue to increase throughout gestation unlike HCG, does not plateau. It shows that kisspeptin may be responsible for establishment of early pregnancy and after that maintaining the pregnancy. Therefore, these results suggest that kisspeptin may be marker of pregnancy in future. Kisspeptin may improve diagnostic accuracy in clinical setting. Limitation of our study was including 6 to 16 weeks only as a study participants.

CONCLUSION

This study demonstrated that kisspeptin is detectable in serum in early pregnancy and increases with gestation throughout pregnancy. Kisspeptin may have clinical utility in developing an accurate test of early pregnancy outcome in the future. Future studies are needed to validate these findings and assess the applicability of the serum kisspeptin assay in pregnancy outcome.

Funding: No funding sources
Conflict of interest: None declared
Ethical approval: The study was approved by the Institutional Ethics Committee

REFERENCES


15. Jayasena CN, Abbara A, Izzi-Engbeaya A, Comminos AN. Reduced levels of plasma kisspeptin during the antenatal booking visit are associated with increased risk of miscarriage. J Clin Endocrinol Metab. 2014;99(12):E2652-E2660.


